$-1.73
(Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
€--
EBITDA
€--
Net Profit
€--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biophytis S.A (BPTSY)
| -- | -- | -- | -- | -83.4 | -85.3 | -- |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
|---|---|
|
Biophytis S.A (BPTSY)
| -87.4 |
|
S&P Small-Cap 600
| 7.0 |
|
BSE Sensex
| 8.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Biophytis S.A (BPTSY)
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the... BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France. Read more
-
Chairman of the Board & CEO
Mr. Stanislas Veillet Ph.D.
-
Chairman of the Board & CEO
Mr. Stanislas Veillet Ph.D.
-
Headquarters
Paris
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Biophytis S.A (BPTSY)
What is the current share price of Biophytis SA (BPTSY) Today?
The share price of Biophytis SA (BPTSY) is $0.25 (NASDAQ) as of 28-Aug-2026 09:30 EDT. Biophytis SA (BPTSY) has given a return of -83.37% in the last 3 years.
What is the current PB & PE ratio of Biophytis SA (BPTSY)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-0.22 |
-0.24 |
2023 |
-0.30 |
-1.32 |
2022 |
-0.33 |
-4.25 |
2021 |
-2.16 |
11.53 |
2020 |
-- |
-- |
What is the 52 Week High and Low of Biophytis SA (BPTSY)?
The 52-week high and low of Biophytis SA (BPTSY) are Rs 0.25 and Rs 0.25 as of 01-Sep-2026.
What is the market cap of Biophytis SA (BPTSY)?
Biophytis SA (BPTSY) has a market capitalisation of $ 7 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Biophytis SA (BPTSY)?
Before investing in Biophytis SA (BPTSY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.